Drug Profile
BEA 2180 BR
Alternative Names: BEA-2180; BEA-2180-BRLatest Information Update: 05 Nov 2014
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antibronchitics; Bronchodilators
- Mechanism of Action Cholinergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 05 Dec 2013 No development reported - Phase-II for Chronic obstructive pulmonary disease in USA, Belgium, Netherlands, Canada, Germany, Hungary, South Korea, Mexico, Poland, Russia, Spain and Taiwan (Inhalation)
- 09 Mar 2013 Adverse events and efficacy data from a phase II trial in Chronic obstructive pulmonary disease released by Boehringer Ingelheim
- 31 May 2009 Boehringer Ingelheim completes a phase II trial in Chronic obstructive pulmonary disease in USA, Canada, Germany, Hungary, South Korea, Mexico, Poland, Russia, Spain and Taiwain (NCT00528996)